Get the Stockscreener App
2.60
19.82%
0.43
Acelyrin Inc stock is traded at $2.60, with a volume of 12.56M.
It is up +19.82% in the last 24 hours and up +30.65% over the past month.
Acelyrin Inc is a late-stage clinical biopharmaceutical company. It is focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating development and commercialization of of transformative medicines.
See More
Previous Close:
$2.17
Open:
$2.555
24h Volume:
12.56M
Relative Volume:
7.28
Market Cap:
$260.85M
Revenue:
-
Net Income/Loss:
$-299.80M
P/E Ratio:
-0.9155
EPS:
-2.84
Net Cash Flow:
$-217.49M
1W Performance:
+22.07%
1M Performance:
+30.65%
6M Performance:
-45.83%
1Y Performance:
-65.97%
1-Day Range:
$2.365
$2.64
1-Week Range:
$2.075
$2.64
52-Week Range:
$1.845
$8.885
Acelyrin Inc Stock (SLRN) Company Profile
Name
Acelyrin Inc
Sector
Industry
Phone
805-871-4300
Address
4149 LIBERTY CANYON RD., AGOURA HILLS
Compare SLRN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SLRN
Acelyrin Inc
|
2.60 | 260.85M | 0 | -299.80M | -217.49M | -2.84 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Acelyrin Inc Stock (SLRN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-14-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jul-08-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-13-23 | Initiated | Wells Fargo | Equal Weight |
| Dec-08-23 | Initiated | Citigroup | Neutral |
| Sep-13-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-05-23 | Initiated | H.C. Wainwright | Buy |
| May-30-23 | Initiated | Jefferies | Buy |
| May-30-23 | Initiated | Morgan Stanley | Overweight |
| May-30-23 | Initiated | Piper Sandler | Overweight |
| May-30-23 | Initiated | TD Cowen | Outperform |
View All
Acelyrin Inc Stock (SLRN) Latest News
Activist investor threatens drug maker's merger plans with L.A. biotech - The Business Journals
Activist investor threatens Peninsula drug maker's merger plans - The Business Journals
Concentra Biosciences, LLC made an Unsolicited Indication of Interest to acquire Acelyrin, Inc. from a group of shareholders for approximately $310 million. - Marketscreener.com
ACELYRIN shares surge on buyout interest By Investing.com - Investing.com Nigeria
ACELYRIN shares surge on buyout interest - Investing.com
Acelyrin Receives Unsolicited Buyout Offer From Concentra Biosciences -February 21, 2025 at 04:38 am EST - Marketscreener.com
Acelyrin confirms unsolicited indication of interest from Concentra Biosciences - TipRanks
ACELYRIN Confirms Receipt Of Unsolicited Indication Of Interest From Concentra Biosciences - Marketscreener.com
Acelyrin, Inc. Confirms Unsolicited Acquisition Proposal from Concentra Biosciences Amidst Ongoing Merger Agreement with Alumis Inc. - Nasdaq
Can This New Cash Offer Derail ACELYRIN's Planned Alumis Merger? - StockTitan
Kuehn Law Encourages HEES, SLRN, PTMN, and IPG Investors to Contact Law Firm - TradingView
SLRN stock touches 52-week low at $1.9 amid market challenges - MSN
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TURN, AMPS, SLRN on Behalf of Shareholders - The Malaysian Reserve
SLRN stock touches 52-week low at $1.85 amid market challenges - MSN
H.C. Wainwright cuts Alumis stock target to $19, maintains Buy rating - MSN
ACELYRIN’s Merger with Alumis - Global Legal Chronicle
After stumbles along winding path, Acelyrin merges with Alumis: Deals Report - BioCentury
Kuehn Law Encourages NVRO, SLRN, TGI, and PTMN Investors to Contact Law Firm - The Malaysian Reserve
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NVRO, SLRN, PLYA on Behalf of Shareholders - The Malaysian Reserve
ACELYRIN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acelyrin, Inc.SLRN - Business Wire
Alumis and Acelyrin to merge in all-stock deal - MSN
The week in pharma: action, reaction and insight – week to February 7 | Pharmaceutical | The Pharmaletter - The Pharma Letter
Alumis To Merge With Acelyrin, But Pause Lonigutamab Program - News & Insights
TYK2s to tango, TED dead? Alumis/Acelyrin merger a capital idea - BioWorld Online
SLRN Shares Experience Decline in Value - Knox Daily
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of ACELYRIN, INC. - PrimePublishers.com
Acelyrin Inc’s (SLRN) Stock Is Harder To Predict Than You Think - Stocks Register
Alumis and ACELYRIN announce merger in all-stock deal - MSN
Alumis and Acelyrin sign merger agreement - Yahoo
Acelyrin Inc (SLRN) Stock: Navigating a Year of Volatility - The InvestChronicle
After big IPO, Peninsula biotech plots merger, big clinical trial readouts - The Business Journals
Nasdaq Neophytes Acelyrin, Alumis Merge to Tackle Immune-Mediated Diseases - BioSpace
Immune drugmakers Alumis and Acelyrin to merge - BioPharma Dive
Alumis and ACELYRIN announce all-stock merger to focus on immune diseases - World Pharmaceutical Frontiers
Alumis stock falls on merger deal with Acelyrin (SLRN:NASDAQ) - Seeking Alpha
Acelyrin to be absorbed into Alumis in all-stock merger - Fierce Biotech
Alumis and Acelyrin merge, with $737 million cash runway - The Pharma Letter
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Acelyrin, Inc.SLRN - The Malaysian Reserve
Alumis and ACELYRIN announce merger in all-stock deal By Investing.com - Investing.com Nigeria
SLRN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of ACELYRIN, Inc. Is Fair to Shareholders - The Bakersfield Californian
Alumis And Acelyrin To Merge Creating A Late-Stage Clinical Biopharma Company - TradingView
Alumis, Acelyrin To Merge Creating A Late-Stage Clinical Biopharma Company -February 06, 2025 at 05:56 pm EST - Marketscreener.com
Alumis, Acelyrin To Merge Creating A Late-Stage Clinical Biopharma Company - TradingView
ACELYRIN, INC. Announces Merger with Alumis Inc. - TipRanks
Shareholder Alert: Ademi & Fruchter LLP investigates whether ACELYRIN, INC. is obtaining a Fair Price for its Public Shareholders - The Bakersfield Californian
Alumis, Acelyrin to merge in all-stock transaction - TipRanks
Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases - The Manila Times
Alumis Inc. and ACELYRIN, Inc. Announce Definitive Merger Agreement to Advance Late-Stage Pipeline and Clinical Development - Nasdaq
Fenwick Represents ACELYRIN in Pending Merger with Alumis - Fenwick & West LLP
ACELYRIN ends key drug development agreement - MSN
Is Acelyrin Inc (SLRN) a good investment opportunity? - US Post News
Acelyrin Inc Stock (SLRN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Acelyrin Inc Stock (SLRN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Lin Shao-Lee | Chief Executive Officer |
Apr 01 '24 |
Sale |
6.63 |
9,961 |
66,024 |
1,577,374 |
0.27%
3.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):